Unleashing Power of AI-Driven Liquid Biopsy
Revolutionary Liquid Biopsy Technology
OncoMaverickDX™ leverages AI to provide a groundbreaking, non-invasive method for early cancer detection. This technology marks a significant advance in diagnosing cancer accurately using a simple blood sample.
Unique Immune Signatures: The Power of mRNA
Our breakthrough lies in the detection of unique immune signatures using mRNA. By analyzing these gene signatures or expressions, our technology can identify cancers early and with remarkable accuracy.
Not only we detect cancers early, by using OncoMaverickDX™ we monitor the treatment response and cancer reoccurance using patient's own immune response.
Harnessing Unique Immune Signatures
Our approach involves detecting unique immune signatures from mRNA in blood samples. These gene expressions, analyzed by our advanced AI algorithms, allow for precise cancer identification, setting us apart from traditional ctDNA and exosome-based methods.
Pioneering Precision in Cancer Diagnostics
Experience the revolutionary potential of AI to transform cancer care, offering rapid and cost-effective solutions for a brighter, healthier future.
The QPCR pioneer biomarker assay at the heart of OncoMaverickDX™ delivers results within 4 hours, offering both speed and affordability. This rapid turnaround ensures timely diagnostic information for effective patient care.
Sensitivity
Specificity
~95%*
Proven Success: Clinical Validation
In our initial study involving 150 patients, OncoMaverickDX™ demonstrated near-perfect sensitivity and specificity across more than 10 types of cancers. These results highlight the reliability and transformative potential of our technology.
Join Us in Revolutionizing Cancer Detection
Biomavericks is dedicated to improving patient outcomes through innovative diagnostics. OncoMaverickDX™ is not just about cutting-edge technology; it’s about making a meaningful impact on patients’ lives.
Explore and Connect
Discover more about our innovative technology, ongoing research, and future advancements. Together, we can redefine the approach to cancer detection.
Our Partners and Collaborators
We believe every client is a valuable long-term partner.
